Tolloid-like 1 gene variant rs17047200, pretreatment FIB-4, ALBI and PALBI scores as predictors of hepatocellular carcinoma occurrence after directly acting antivirals

Ahmed Kamal; Ali Mohsin; Cecil Matta; Ramy Ghazy; Abeer Elhadidi; Mona Tahoun; Amr Rahal; Donia Domiaty; Nema Mohamed

doi:10.5114/ceh.2022.122289

eISSN: 2449-8238
ISSN: 2392-1099

Clinical and Experimental Hepatology

Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2022
vol. 8

Send email

Copy url:

abstract:

Original paper

Tolloid-like 1 gene variant rs17047200, pretreatment FIB-4, ALBI and PALBI scores as predictors of hepatocellular carcinoma occurrence after directly acting antivirals

Ahmed Kamal

¹

,

Ali Kareem Mohsin

^{2, 3}

,

Cecil Matta

³

,

Ramy Mohamed Ghazy

⁴

,

Abeer Elhadidi

¹

,

Mona Tahoun

¹

,

Amr Rahal

¹

,

Donia Domiaty

¹

,

Nema Mohamed

³

Faculty of Medicine, Alexandria University, Egypt
University of Warith Al Anbiyaa, Iraq
Faculty of Science, Alexandria University, Egypt
High Institute of Public Health, Alexandria University, Egypt

Clin Exp HEPATOL 2022; 8, 4: 330-334

DOI: https://doi.org/10.5114/ceh.2022.122289

Online publish date: 2022/12/28

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Kamal A, Mohsin AK, Matta C, et al. Tolloid-like 1 gene variant rs17047200, pretreatment FIB-4, ALBI and PALBI scores as predictors of hepatocellular carcinoma occurrence after directly acting antivirals. Clinical and Experimental Hepatology. 2022;8(4):330-334. doi:10.5114/ceh.2022.122289.

APA

Kamal, A., Mohsin, A. K., Matta, C., Ghazy, R. M., Elhadidi, A.,  & Tahoun, M. et al. (2022). Tolloid-like 1 gene variant rs17047200, pretreatment FIB-4, ALBI and PALBI scores as predictors of hepatocellular carcinoma occurrence after directly acting antivirals. Clinical and Experimental Hepatology, 8(4), 330-334. https://doi.org/10.5114/ceh.2022.122289

Chicago

Kamal, Ahmed, Ali K Mohsin, Cecil Matta, Ramy M Ghazy, Abeer Elhadidi, Mona Tahoun,  and Amr Rahal et al. 2022. "Tolloid-like 1 gene variant rs17047200, pretreatment FIB-4, ALBI and PALBI scores as predictors of hepatocellular carcinoma occurrence after directly acting antivirals". Clinical and Experimental Hepatology 8 (4): 330-334. doi:10.5114/ceh.2022.122289.

Harvard

Kamal, A., Mohsin, A., Matta, C., Ghazy, R., Elhadidi, A., Tahoun, M., Rahal, A., Domiaty, D.,  and Mohamed, N. (2022). Tolloid-like 1 gene variant rs17047200, pretreatment FIB-4, ALBI and PALBI scores as predictors of hepatocellular carcinoma occurrence after directly acting antivirals. Clinical and Experimental Hepatology, 8(4), pp.330-334. https://doi.org/10.5114/ceh.2022.122289

MLA

Kamal, Ahmed et al. "Tolloid-like 1 gene variant rs17047200, pretreatment FIB-4, ALBI and PALBI scores as predictors of hepatocellular carcinoma occurrence after directly acting antivirals." Clinical and Experimental Hepatology, vol. 8, no. 4, 2022, pp. 330-334. doi:10.5114/ceh.2022.122289.

Vancouver

Kamal A, Mohsin A, Matta C, Ghazy R, Elhadidi A, Tahoun M et al. Tolloid-like 1 gene variant rs17047200, pretreatment FIB-4, ALBI and PALBI scores as predictors of hepatocellular carcinoma occurrence after directly acting antivirals. Clinical and Experimental Hepatology. 2022;8(4):330-334. doi:10.5114/ceh.2022.122289.

PlumX metrics:

Aim of the study
Identifying persons at increased risk of developing hepatocellular carcinoma (HCC) after exposure to directly acting antivirals (DAAs) is of utmost importance. Our aim was to identify the predictors of de novo HCC occurrence among cirrhotic patients after hepatitis C virus (HCV) treatment using DAAs.

Material and methods
529 cirrhotic patients who initiated treatment for HCV using DAAs were followed up for 2 years from the end of treatment for development of HCC. Pretreatment clinical and laboratory data were assessed as possible predictors for HCC occurrence. Genotyping for tolloid-like 1 gene (TLL1) variant rs17047200 was assessed in all patients who developed HCC and in the matched control group.

Results
Pretreatment bilirubin, FIB-4 and platelet-albumin-bilirubin (PALBI) scores were significantly higher among those who developed HCC than those who did not develop HCC during the 2-year follow-up period while hemoglobin level was significantly lower. ROC curve analysis revealed that at a cut-off ≥ 3.07, pretreatment FIB-4 had a sensitivity of 76.5%, and negative predictive value (NPV) of 92%. At a cut-off ≥ –2.5, pretreatment PALBI score had a sensitivity of 82.4%, and NPV of 93.2%. Regarding genotyping for TLL1 rs17047200 there were no statistically significant differences between those who developed HCC during follow-up and the matched control group.

Conclusions
TLL1 rs17047200 genotyping is not helpful in predicting HCC occurrence after DAAs. On the other hand, lower pretreatment hemoglobin level and higher pretreatment bilirubin, FIB-4 and PALBI scores are associated with higher risk of HCC development after DAAs.

keywords:

Tolloid-like 1 gene variant rs17047200, pretreatment FIB-4, ALBI and PALBI scores as predictors of hepatocellular carcinoma occurrence after directly acting antivirals

Ahmed Kamal 1 , Ali Kareem Mohsin 2, 3 , Cecil Matta 3 , Ramy Mohamed Ghazy 4 , Abeer Elhadidi 1 , Mona Tahoun 1 , Amr Rahal 1 , Donia Domiaty 1 , Nema Mohamed 3

hepatocellular carcinoma, chronic hepatitis C, antiviral agents, genetic predictive testing, tolloid-like 1 gene

Ahmed Kamal

¹

,

Ali Kareem Mohsin

^{2, 3}

,

Cecil Matta

³

,

Ramy Mohamed Ghazy

⁴

,

Abeer Elhadidi

¹

,

Mona Tahoun

¹

,

Amr Rahal

¹

,

Donia Domiaty

¹

,

Nema Mohamed

³